| アブストラクト | Depression persists as one of the illnesses described relentlessly through the centuries because it affects a large group of people. Background/Objectives: The treatment of depression consists of various therapeutic agents, among which selective serotonin reuptake inhibitors (SSRIs) are elective. As polypharmacy tends to become the norm in modern days, the study of the real-life occurrence of drug-drug interactions is imperative. The aim of this study was the evaluation of drug-drug interactions (DDIs) between antidepressant medicines, namely SSRIs (each representative) versus eleven representatives from other antidepressant classes. Methods: Based on the spontaneous safety reports (ICSRs) uploaded to EudraVigilance until the end of July 2024, the descriptive and the disproportionality analyses were performed, and results were interpreted in the context of pharmacologic variability. Results: SSRIs were the focus of 137,369 ICSRs while for the other antidepressants, namely amitriptyline, clomipramine, duloxetine, venlafaxine, mirtazapine, bupropion, trazodone, tianeptine, agomelatine, brexpiprazole, and esketamine, a total of 155,458 reports were registered. The most notable differences appeared in psychiatric adverse drug reactions. Except fluvoxamine (n = 463), the remaining SSRIs had a higher number of DDIs reported (n = 1049 for escitalopram and n = 1549 for sertraline) compared to other antidepressants. However, similar numbers of DDIs were reported for duloxetine (n = 1252) and venlafaxine (n = 1513). Sertraline unspecified DDIs were reported with a higher probability compared to all other drugs (e.g., esketamine ROR: 9.37, 95% CI: 5.17-16.96, tianeptine ROR: 4.08, 95% CI: 2.49-6.69, etc.). Conclusions: SSRIs, although known to influence various cytochrome P450 isoenzymes, have not shown higher inhibitory interactions compared to any of the drugs selected as reference. Sertraline appears in more reports concerning DDIs than the other antidepressants. Still, further real world studies related to the DDIs of SSRIs are needed to complete the relevant knowledge level. |
|---|
| ジャーナル名 | Journal of clinical medicine |
|---|
| Pubmed追加日 | 2025/2/26 |
|---|
| 投稿者 | Dobrea, Carmen Maximiliana; Morgovan, Claudiu; Frum, Adina; Butuca, Anca; Chis, Adriana Aurelia; Arseniu, Anca Maria; Ghibu, Steliana; Vonica, Razvan Constantin; Gligor, Felicia Gabriela; Ilie, Ioana Rada Popa; Vonica Tincu, Andreea Loredana |
|---|
| 組織名 | Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu,;550169 Sibiu, Romania.;Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy,;"Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca,;Romania.;Department of Endocrinology, Faculty of Medicine, "Iuliu Hatieganu" University of;Medicine and Pharmacy, 3-5 Louis Pasteur Street, 400349 Cluj-Napoca, Romania. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40004740/ |
|---|
